Published online before print October 18, 2004, doi: 10.1161/01.HYP.0000146483.78994.56
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;44:913.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition
From the Centre for Cardiovascular Science, University of Edinburgh, Royal Infirmary of Edinburgh, United Kingdom.
Reprint requests to Dr N.L.M. Cruden, Centre for Cardiovascular Science, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK, EH16 4SB. E-mail nick.cruden{at}ed.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Angiotensin-converting enzyme and neutral endopeptidase (EC 3.4.24.11; neprilysin) are metallopeptidases present on the endothelium that metabolize bradykinin. Inhibitors of angiotensin-converting enzyme potentiate bradykinin-mediated vasodilatation and endothelial tissue plasminogen activator release. Combined angiotensin-converting enzyme and neutral endopeptidase inhibition may have additional beneficial cardiovascular effects mediated through bradykinin potentiation. We investigated the effects of local neutral endopeptidase inhibition on the vascular actions of bradykinin in heart failure patients maintained on chronic angiotensin-converting enzyme inhibition. Ten patients received intrabrachial infusion of thiorphan (30 nmol/min), a neutral endopeptidase inhibitor, in a randomized double-blind placebo-controlled crossover trial. Thiorphan was coinfused with Lys-des-Arg9-bradykinin (1 to 10 nmol/min), bradykinin (30 to 300 pmol/min), atrial natriuretic peptide (10 to 100 pmol/min), and sodium nitroprusside (2 to 8 µg/min). Bradykinin, atrial natriuretic peptide, and sodium nitroprusside caused dose-dependent vasodilatation (peak blood flow 14.4±2.2, 3.6±0.6, and 8.6±1.3 mL per 100 mL/min, respectively; P<0.0001). Bradykinin caused dose-dependent increases in tissue plasminogen activator antigen and activity (peak concentration 31.8±3.4 ng/mL and 21.9±7.6 IU/mL, respectively; P<0.001) and estimated antigen and activity release (peak release 152±46 ng per 100 mL/min and 154±22 IU/100 mL/min, respectively; P<0.005). Compared with placebo, thiorphan augmented bradykinin-mediated vasodilatation (1.4-fold; P<0.0001) and net tissue plasminogen activator release (1.5-fold; P<0.005). Neutral endopeptidase contributes to bradykinin metabolism in heart failure patients maintained on angiotensin-converting enzyme inhibitor therapy. Our findings may explain some of the clinical effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition, including the greater vasodepressor effect observed with combined therapy when compared with angiotensin-converting enzyme inhibition alone.
Key Words: heart failure • angiotensin-converting enzyme • bradykinin • endothelium
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Bradykinin is a potent endothelium-dependent vasodilator peptide released at sites of inflammation and coagulation. Apart from vasodilatation, it also stimulates endothelial release of the prolytic factor tissue-type plasminogen activator (t-PA), and these effects are mediated by the constitutively expressed B2 receptor.1,2 Removal of the C-terminal arginine from bradykinin results in formation of des-Arg9-bradykinin, the principal ligand for the B1 kinin receptor in plasma.3 However, the most potent endogenous ligand for the B1 kinin receptor is Lys-des-Arg9-bradykinin.3 The vascular B1 receptor is normally expressed very weakly but is markedly upregulated in the presence of inflammation, cardiovascular disease, and angiotensin-converting enzyme (ACE) inhibition,4 where it also mediates vasodilatation.3
ACE is the principal enzyme responsible for the rapid turnover of bradykinin (plasma half life 
15 seconds) and its metabolites.3 It has been widely established that ACE inhibitors improve morbidity and mortality in patients with heart failure,5 and these benefits may be due, at least in part, to inhibition of bradykinin metabolism.6,7 ACE inhibition increases the plasma half lives of bradykinin and des-Arg9-bradykinin 9 and 2-fold, respectively,8 and at a functional level, potentiates the vascular actions of bradykinin in the human forearm1,9 and coronary10 circulations. Moreover, bradykinin antagonism causes vasoconstriction7 and attenuates the fall in blood pressure6 in patients treated with ACE inhibitor therapy.
Neutral endopeptidase (EC 3.4.24.11; neprilysin [NEP]) is a membrane-bound metallopeptidase that colocalizes with ACE and metabolizes a number of vasodilator and vasoconstrictor peptides, including atrial natriuretic peptide, substance P, endothelin-1, and bradykinin.11 NEP expression is upregulated in heart failure patients,12,13 and in the presence of ACE inhibition, the contribution of NEP to bradykinin metabolism is increased.14 NEP inhibition potentiates the half life of bradykinin15 and augments bradykinin-mediated vasodilatation in vitro.16 It is not known whether NEP inhibition augments the half life of Lys-des-Arg9-bradykinin. Indeed, it has been suggested that the Phe8 residue may protect B1 ligands from degradation by NEP.3 Although the effects of NEP inhibition on systemic hemodynamics are variable,17–20 clinical improvements have been reported during NEP inhibition in heart failure patients.21
Coadministration of ACE and NEP inhibitors may confer additional therapeutic efficacy. Combined ACE and NEP inhibition attenuates bradykinin degradation more effectively than either enzyme alone,22 and in animal models, improves cardiac remodeling and survival to a greater extent than isolated ACE inhibition.23 These cardioprotective effects are lost in transgenic mice lacking the B2 kinin receptor.24 In man, combined ACE and NEP inhibition reduces blood pressure to a greater extent than inhibition of either enzyme alone19,25 and is associated with symptomatic and hemodynamic improvements in heart failure patients.26 The hypothesis that combined ACE and NEP inhibition may improve symptoms and survival in heart failure patients to a greater extent than ACE inhibition alone has been evaluated recently in a large-scale clinical trial (Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events [OVERTURE]).27
We demonstrated previously that chronic ACE inhibition potentiates bradykinin-mediated vasodilatation and endothelial release of t-PA in forearm circulation of heart failure patients.1 The aims of this study were to investigate whether local NEP inhibition augments the vascular actions of bradykinin and to examine the effects of B1 receptor agonism in heart failure patients maintained on long-term ACE inhibitor therapy.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patients
Ten patients with symptomatic heart failure and echocardiographic evidence of left ventricular systolic dysfunction attended, fasted at 9 AM on 2 occasions at least 2 weeks apart. The protocol was performed with the approval of the local ethics committee, in accordance with the Declaration of Helsinki and with the written informed consent of each patient. Patients were maintained on maximally tolerated ACE inhibitor therapy (ramipril 10 mg daily [n=4] and 5 mg daily [n=3]; enalapril 20 mg daily [n=1] and 10 mg daily [n=1]; and lisinopril 40 mg daily [n=1]) for at least 6 months before recruitment. On the morning of each visit, ACE inhibitor therapy was administered at 8 AM and diuretics were withheld.
Measurements
Bilateral forearm blood flow was measured using venous occlusion plethysmography.1,7,9,28 Heart rate and blood pressure were recorded in the noninfused arm using a semiautomated noninvasive oscillometric sphygmomanometer (Takeda UA 751; Takeda) at baseline and in the final minute of each drug infusion period, after forearm blood flow measurements and venous sampling.
Venous cannulae (17-gauge) were inserted bilaterally into a large antecubital vein. Throughout each study, 10 mL of blood was collected from each arm into acidified buffered citrate (Biopool Stabilyte; Umeå; for t-PA assays) and citrate (Monovette, Sarstedt, Numbrecht; for plasminogen activator inhibitor-1 [PAI-1] assays). Platelet-free plasma was prepared as described previously1,28 and stored at –80°C before assay. Plasma concentrations of t-PA and PAI-1 antigen were determined using an ELISA, t-PA activity using a photometric method,28 and ACE activity using colorimetric spectrophotometry (reference range 8 to 55 U/L; Sigma).29
Study Protocol
A 27-gauge steel needle was inserted into the brachial artery of the nondominant arm. After 15 minutes equilibration with an infusion of 0.9% saline, patients were randomized to receive an intrabrachial infusion of thiorphan (30 nmol/min; Clinalfa AG) or saline placebo for 3 hours. The dose of thiorphan was chosen based on previous forearm studies30 to achieve a local plasma concentration >10-fold the IC50 of thiorphan for NEP in vitro.31 Thiorphan or placebo was coinfused with bradykinin (30, 100, and 300 pmol/min; Clinalfa AG),7 Lys-des-Arg9-bradykinin (1, 3, and 10 nmol/min; Clinalfa AG), atrial natriuretic peptide (10, 30, and 100 pmol/min; Clinalfa AG),32 and sodium nitroprusside (2, 4, and 8 µg/min; David Bull Laboratories)28 for 10 minutes at each dose. There was a 20-minute washout infusion of 0.9% saline between compounds. The order of infusion was randomized between patients but was maintained for both visits. The doses of Lys-des-Arg9-bradykinin were chosen based on binding affinity data33 and the hypotensive dose response in rodents and nonhuman primates.34,35 The combined rate of infusion remained constant throughout each study at 1 mL/min.
Data Analysis and Statistics
Plethysmographic data were extracted from Chart data files, and forearm blood flow was calculated as described previously.1,28 Estimated net release of t-PA antigen and activity were calculated as the product of infused forearm plasma flow and the t-PA concentration difference between the infused and noninfused arms.1,28 Statistical analyses were performed using ANOVA or, where appropriate, paired t tests.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
There were no significant differences in heart rate, blood pressure, or baseline forearm blood flow during or between study days (Table 1). Consistent with previous studies,2 1 subject developed transient upper limb edema with 300 pmol/min of bradykinin that rapidly resolved on cessation of the infusion. There were no other reported side effects.
|
Plasma ACE Activity
Baseline plasma ACE activity was similar between thiorphan and placebo study visits (12.3±2.6 versus 9.7±1.5 U/mL, respectively; P=0.7). Compared with baseline, there were no significant differences in plasma ACE activity measured after 90 minutes of thiorphan (10.7±2.5 U/mL; P=0.3) or placebo (10.2±1.7 U/mL; P=0.3) coinfusion.
Forearm Blood Flow Responses
Bradykinin, atrial natriuretic peptide, and sodium nitroprusside caused dose-dependent increases in forearm blood flow in all studies (P<0.0001 for all; Figure 1). Forearm blood flow did not change during Lys-des-Arg9-bradykinin infusion (Figure 1). Compared with saline placebo, coinfusion of thiorphan augmented forearm vasodilatation to bradykinin (P<0.0001; Figure 1) but not atrial natriuretic peptide or sodium nitroprusside.
|
) on infused forearm blood flow during intra-arterial infusion of bradykinin, sodium nitroprusside, atrial natriuretic peptide, and Lys-des-Arg9-bradykinin (*P<0.0001, ANOVA dose response; 
P<0.0001, ANOVA thiorphan vs placebo).
Plasma Fibrinolytic Factors
There were no significant differences in baseline plasma t-PA antigen (10.8±0.9 versus 9.8±0.9 ng/mL), t-PA activity (0.1±0.1 versus 0.4±0.1), or PAI-1 antigen concentrations (37.3±3.7 versus 38.4±6.2 ng/mL) between thiorphan and placebo, respectively. Bradykinin caused a dose-dependent increase in plasma t-PA antigen and activity concentrations in the infused arm (P<0.001 for all; Table 2) and the net release of t-PA antigen and activity in all studies (P<0.005 for all; Figure 2). Compared with placebo, thiorphan augmented the increase in plasma t-PA activity concentration (21.9±2.4 versus 24.8±2.6 IU/mL, respectively at bradykinin, 300 pmol/min; P<0.05; Table 2) in the infused arm and the net release of t-PA antigen (157±46 versus 233±46 ng per 100 mL/min, respectively at bradykinin, 300 pmol/min; P<0.005; Figure 2) and activity (155±22 versus 244±51 ng per 100 mL/min, respectively at bradykinin, 300 pmol/min; P<0.005; Figure 2). There was a trend toward an increase in t-PA antigen in the infused arm during thiorphan infusion compared with placebo (32.5±3.4 versus 36.5±4.2 ng/mL, respectively at bradykinin, 300 pmol/min; P=0.058; Table 2). Because of systemic overspill, bradykinin increased plasma t-PA antigen and activity concentrations in the noninfused arm (P<0.01 and P<0.05, respectively; Table 2) that, for t-PA activity, was greater during thiorphan infusion (P<0.05; Table 2). There were no significant changes in t-PA antigen, activity, or net t-PA release during infusion of atrial natriuretic peptide or Lys-des-Arg9-bradykinin.
|
|
There was a significant reduction in plasma PAI-1 antigen concentrations in the infused arm during bradykinin coinfusion with thiorphan (baseline 33.3±3.5 versus 29.4±3.4 ng/mL at bradykinin, 300 pmol/min; P<0.05) but not placebo. There were no significant changes in PAI-1 antigen concentration during infusion of Lys-des-Arg9-bradykinin or atrial natriuretic peptide.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
For the first time, we demonstrated that acute local NEP inhibition augments bradykinin-mediated endothelium-dependent vasodilatation and endogenous t-PA release in heart failure patients maintained on chronic ACE inhibitor therapy. In addition, this is the first clinical study to show that the B1 receptor does not mediate vasodilatation or endothelial t-PA release in these patients. Our findings support the hypothesis that bradykinin may contribute to the systemic hemodynamic differences observed between combined ACE and NEP inhibition, and ACE inhibition alone.
Clinical Implications
There is now substantial evidence that bradykinin contributes to the systemic hemodynamic and anti-ischemic effects of ACE inhibitor therapy.1,6,7,36 Our findings suggest that bradykinin-mediated vasodilatation may contribute to the greater vasodepressor actions demonstrated with combined ACE and NEP inhibition compared with isolated ACE inhibition.19,25 Moreover, despite the marked increase in bradykinin-induced t-PA release by ACE inhibition alone,1 additional NEP inhibition causes further substantial augmentation of acute t-PA release. Together, these hemodynamic and profibrinolytic effects would be expected to have important therapeutic consequences. However, in the recent OVERTURE trial27 of heart failure patients, treatment with omapatrilat, a combined ACE and NEP inhibitor, failed to reduce all-cause mortality when compared with enalapril, although it did reduce the combined secondary end point of cardiovascular death and hospitalization. Post hoc analysis redefining end points according to the Studies of Left Ventricular Dysfunction (SOLVD) criteria suggested that omapatrilat may be more effective at preventing cardiovascular events than enalapril, but that the additional benefit was substantially smaller than anticipated.27 This may, in part, reflect the shorter duration of NEP inhibition compared with ACE inhibition with omapatrilat.37 Given our findings, pharmacological strategies offering a more balanced and prolonged duration of combined ACE and NEP inhibition may confer greater cardiovascular benefits.
Augmentation of bradykinin-mediated vasodilatation within the kidney may also contribute to the greater increase in renal blood flow observed with combined ACE and NEP inhibition than ACE inhibition alone.38 As a result, it has been suggested that combined ACE and NEP inhibition may afford greater renal protection than ACE inhibition alone.38 However, it should be noted that potentiating the vascular actions of kinins may have detrimental effects. Bradykinin has been implicated in the pathogenesis of ACE inhibitor–mediated angioedema.39 An even greater incidence of angioedema has been reported after treatment with combined ACE and NEP inhibition.40 Our findings are consistent with the suggestion that bradykinin may contribute to this rare but potentially life-threatening side effect.
Role of B1 Receptor
We demonstrated that intra-arterial Lys-des-Arg9-bradykinin, a potent and highly selective agonist at the human B1 kinin receptor, has no effect on blood flow or endothelial t-PA release in the forearm circulation of heart failure patients maintained on long-term ACE inhibitor therapy. This is in contrast to our previous findings that combined B1 and B2 receptor blockade, but not isolated selective blockade of the B2 receptor causes vasoconstriction in heart failure patients treated with ACE inhibition.7 We infused Lys-des-Arg9-bradykinin at a dose that would achieve a local plasma concentration 20x greater than those shown previously to produce 50% of the maximal vasomotor response in human33 and animal studies,34,35 and therefore, our findings are unlikely to reflect an inadequate dose. Additional clinical studies using a selective B1 kinin receptor antagonist are now required to more fully investigate the role of the vascular B1 receptor in man.
Atrial Natriuretic Peptide and Neutral Endopeptidase
Consistent with previous work demonstrating an impaired forearm vasodilator response to atrial natriuretic peptide in heart failure patients,32,41,42 atrial natriuretic peptide caused a modest dose-dependent increase in forearm blood flow that was not augmented by local NEP inhibition. Although suppression of PAI-1 expression in endothelial cells has been reported in vitro,43 we report for the first time that intra-arterial atrial natriuretic peptide does not directly alter either plasma PAI-1 or t-PA antigen concentrations in vivo in man.
Local NEP inhibition did not potentiate atrial natriuretic peptide–mediated forearm vasodilatation, in keeping with previous data demonstrating that intrabrachial thiorphan (30 nmol/min) does not increase endogenous plasma atrial natriuretic peptide concentrations in human forearm circulation.30 At first, this may appear surprising given that systemic NEP inhibition augments plasma atrial natriuretic peptide concentrations in heart failure patients.21 However, it is likely to reflect differences in the rate of clearance of atrial natriuretic peptide and bradykinin from forearm circulation. The half life of atrial natriuretic peptide (5 minutes) is greater than that of bradykinin (15 seconds). Assuming a transit time of the forearm vascular bed of 30 seconds, NEP inhibition with intrabrachial thiorphan is unlikely to result in sufficient local accumulation of atrial natriuretic peptide to augment forearm vasomotor responses. Moreover, the natriuretic peptide C receptor contributes equally to the clearance of plasma atrial natriuretic peptide, and this pathway is unaffected by NEP inhibition.
Study Limitation
Although selective for NEP, thiorphan may cause some inhibition of ACE activity, and theoretically, our findings could represent further inhibition of ACE activity. Thiorphan exists as 2 enantiomers that, although equipotent for NEP inhibition, have differing potencies against ACE: selectivity of NEP compared with ACE inhibition of 50-fold for S-thiorphan and 200-fold for R-thiorphan.11 The preparation of thiorphan used in this study contains equal proportions of both isomers.11 We do not believe the effects of thiorphan were mediated through additional inhibition of ACE activity because local thiorphan infusion did not alter plasma ACE activity. Moreover, in a previous study30 using the same dose of thiorphan, there were no effects on plasma angiotensin II concentrations in forearm circulation of healthy volunteers treated acutely with enalapril. However, we acknowledge that ACE inhibition by maximally tolerated doses of an ACE inhibitor may be incomplete,44 and we cannot completely exclude a contribution of additional ACE inhibition to our study findings.
Perspectives
We have demonstrated that local NEP inhibition augments bradykinin-mediated vasodilatation and endothelial t-PA release in heart failure patients maintained on long-term ACE inhibitor therapy. Using a potent B1 receptor agonist, we have shown that isolated stimulation of the B1 kinin receptor does not cause vasodilatation or endothelial t-PA release in man. These findings confirm that NEP contributes to bradykinin metabolism in heart failure patients and suggest that potentiation of the vascular and profibrinolytic actions of bradykinin may explain some of the observed effects in recent clinical trials of combined ACE and NEP inhibitor therapy.
|
Acknowledgments |
|---|
N.L.M.C. was supported by a junior cardiovascular research fellowship (Pfizer UK Ltd). This work was supported by the British Heart Foundation (PG/02/113). We would like to thank Pamela Dawson for performing the fibrinolytic assays.
|
Footnotes |
|---|
Drs Cruden and Newby have received funding from Pfizer UK Ltd in the form of an unrestricted educational award. Pfizer UK Ltd was not involved in any aspect of study design, data collection and interpretation, writing of this manuscript, or the decision to publish.
Received August 27, 2004; first decision September 11, 2004; accepted September 20, 2004.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J Am Coll Cardiol. 2002; 40: 961–966.
2. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation. 2000; 102: 2190–2196.
3. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev. 1998; 50: 357–386.
4. Marin-Castano ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader JL, Girolami JP, Bascands JL. Induction of functional bradykinin B1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 2002; 105: 627–632.
5. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: 1429–1435.[Abstract]
6. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998; 339: 1285–1292.
7. Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation. 2001; 104: 2177–2181.
8. Cyr M, Lepage Y, Blais C Jr, Gervais N, Cugno M, Rouleau JL, Adam A. Bradykinin and des-Arg9-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol. 2001; 281: H275–H283.
9. Benjamin N, Cockcroft JR, Collier JG, Dollery CT, Ritter JM, Webb DJ. Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol. 1989; 412: 543–555.
10. Kuga T, Mohri M, Egashira K, Hirakawa Y, Tagawa T, Shimokawa H, Takeshita A. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J Am Coll Cardiol. 1997; 30: 108–112.[Abstract]
11. Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993; 45: 87–146.[Medline] [Order article via Infotrieve]
12. Fielitz J, Dendorfer A, Pregla R, Ehler E, Zurbrugg HR, Bartunek J, Hetzer R, Regitz-Zagrosek V. Neutral endopeptidase is activated in cardiomyocytes in human aortic valve stenosis and heart failure. Circulation. 2002; 105: 286–289.
13. Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M, Willnow T, Bruemmer D, Graf K, Dietz R, Willenbrock R. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci. 2002; 71: 2701–2712.[CrossRef][Medline] [Order article via Infotrieve]
14. Dumoulin MJ, Adam A, Blais C Jr, Lamontagne D. Metabolism of bradykinin by the rat coronary vascular bed. Cardiovasc Res. 1998; 38: 229–236.
15. Graf K, Grafe M, Bossaller C, Niehus J, Schulz KD, Auch-Schwelk W, Fleck E. Degradation of bradykinin by neutral endopeptidase (EC 3.4.24.11) in cultured human endothelial cells. Eur J Clin Chem Clin Biochem. 1993; 31: 267–272.[Medline] [Order article via Infotrieve]
16. Krassoi I, Pataricza J, Papp JG. Thiorphan enhances bradykinin-induced vascular relaxation in hypoxic/hyperkalaemic porcine coronary artery. J Pharm Pharmacol. 2003; 55: 339–345.[CrossRef][Medline] [Order article via Infotrieve]
17. Northridge DB, Jardine AG, Alabaster CT, Barclay PL, Connell JM, Dargie HJ, Dilly SG, Findlay IN, Lever AF, Samuels GM. Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet. 1989; 2: 591–593.[Medline] [Order article via Infotrieve]
18. Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M, Cussans N. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension. 1990; 16: 269–276.
19. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, Brunner HR. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 1995; 13: 797–804.[Medline] [Order article via Infotrieve]
20. Bevan EG, Connell JM, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992; 10: 607–613.[Medline] [Order article via Infotrieve]
21. Northridge DB, Newby DE, Rooney E, Norrie J, Dargie HJ. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J. 1999; 138: 1149–1157.[CrossRef][Medline] [Order article via Infotrieve]
22. Dumoulin MJ, Adam A, Rouleau JL, Lamontagne D. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol. 2001; 37: 359–366.[CrossRef][Medline] [Order article via Infotrieve]
23. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol. 1999; 34: 782–790.[CrossRef][Medline] [Order article via Infotrieve]
24. Xu J, Carretero OA, Liu YH, Yang F, Shesely EG, Oja-Tebbe N, Yang XP. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail. 2004; 10: 83–89.[Medline] [Order article via Infotrieve]
25. Campese VM, Lasseter KC, Ferrario CM, Smith WB, Ruddy MC, Grim CE, Smith RD, Vargas R, Habashy MF, Vesterqvist O, Delaney CL, Liao WC. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension. 2001; 38: 1342–1348.
26. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol. 2000; 36: 479–486.
27. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002; 106: 920–926.
28. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997; 78: 1242–1248.[Medline] [Order article via Infotrieve]
29. Holmquist B, Bunning P, Riordan JF. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem. 1979; 95: 540–548.[CrossRef][Medline] [Order article via Infotrieve]
30. Ferro CJ, Spratt JC, Haynes WG, Webb DJ. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation. 1998; 97: 2323–2330.
31. Barclay PL, Danilewicz JC, Samuels GM. Inhibitory potencies of UK-69 578 and thiorphan. Lancet. 1990; 336: 754–755.[Medline] [Order article via Infotrieve]
32. van der Zander K, Houben AJ, Kroon AA, de Leeuw PW. Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. Cardiovasc Res. 1999; 44: 595–600.
33. Gobeil F, Pheng LH, Badini I, Nguyen-Le XK, Pizard A, Rizzi A, Blouin D, Regoli D. Receptors for kinins in the human isolated umbilical vein. Br J Pharmacol. 1996; 118: 289–294.[Medline] [Order article via Infotrieve]
34. Drapeau G, Deblois D, Marceau F. Hypotensive effects of Lys-des-Arg9-bradykinin and metabolically protected agonists of B1 receptors for kinins. J Pharmacol Exp Ther. 1991; 259: 997–1003.
35. Deblois D, Horlick RA. Endotoxin sensitization to kinin B1 receptor agonist in a non-human primate model: haemodynamic and pro-inflammatory effects. Br J Pharmacol. 2001; 132: 327–335.[CrossRef][Medline] [Order article via Infotrieve]
36. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 2003; 107: 579–585.
37. Azizi M, Lamarre-Cliche M, Labatide-Alanore A, Bissery A, Guyene TT, Menard J. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. J Am Soc Nephrol. 2002; 13: 2454–2463.
38. Regamey F, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal hemodynamic and natriuretic effects of concomitant angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension. 2002; 40: 266–272.
39. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998; 351: 1693–1697.[CrossRef][Medline] [Order article via Infotrieve]
40. Armstrong PW, Lorell BH, Nissen S, Borer J. Omapatrilat. Circulation. 2002; 106: e9011e–e9012.
41. Cockcroft JR, Allen MJ, Benjamin N, Webb DJ. The effect of local angiotensin converting enzyme inhibition on the action of atrial natriuretic peptide in the human forearm. J Hum Hypertens. 1989; 3: 49–52.[Medline] [Order article via Infotrieve]
42. Hirooka Y, Takeshita A, Imaizumi T, Suzuki S, Yoshida M, Ando S, Nakamura M. Attenuated forearm vasodilataive response to intra-arterial atrial natriuretic peptide in patients with heart failure. Circulation. 1990; 82: 147–153.
43. Pawlowska Z, Jerczynska H, Szemraj J, Baranska P, Swiatkowska M, Cierniewski CS. Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell Mol Biol Lett. 2002; 7: 1153–1157.[Medline] [Order article via Infotrieve]
44. Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, Hammer A, Sonnenblick EH, Le Jemtel TH. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation. 2000; 101: 844–846.
This article has been cited by other articles:
 |
|
 |
|
  A. Fleischmann, T. Schlomm, H. Huland, J. Kollermann, P. Simon, M. Mirlacher, G. Salomon, F. H.K. Chun, T. Steuber, R. Simon, et al. Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients Clin. Cancer Res., December 1, 2008; 14(23): 7838 - 7842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maloyan, J. Gulick, C. G. Glabe, R. Kayed, and J. Robbins Exercise reverses preamyloid oligomer and prolongs survival in {alpha}B-crystallin-based desmin-related cardiomyopathy PNAS, April 3, 2007; 104(14): 5995 - 6000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Oliver, D. J. Webb, and D. E. Newby Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2470 - 2479. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||